475 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Orphan designations Remove Orphan designations filter
Medicine type
Additional monitoring Remove Additional monitoring filter
Exceptional circumstances Remove Exceptional circumstances filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Erleada
apalutamide, Prostatic Neoplasms
Date of authorisation: 14/01/2019,
, Revision: 2, Authorised, Last updated: 17/12/2020
-
List item
Human medicine European public assessment report (EPAR): Isturisa
Osilodrostat phosphate, Cushing Syndrome
Date of authorisation: 09/01/2020,, 
, Revision: 3, Authorised, Last updated: 17/12/2020
-
List item
Human medicine European public assessment report (EPAR): Revlimid
lenalidomide, Multiple Myeloma, Lymphoma, Mantle-Cell, Myelodysplastic Syndromes
Date of authorisation: 14/06/2007,, Revision: 43, Authorised, Last updated: 17/12/2020
-
List item
Human medicine European public assessment report (EPAR): Deltyba
Delamanid, Tuberculosis, Multidrug-Resistant
Date of authorisation: 27/04/2014,
Date of refusal: 25/07/2013,, , 
, Revision: 14, Authorised, Last updated: 17/12/2020
-
List item
Human medicine European public assessment report (EPAR): Quinsair
levofloxacin, Cystic Fibrosis, Respiratory Tract Infections
Date of authorisation: 25/03/2015,, Revision: 12, Authorised, Last updated: 15/12/2020
-
List item
Human medicine European public assessment report (EPAR): Polivy
polatuzumab vedotin, Lymphoma, B-Cell
Date of authorisation: 16/01/2020,, , , Revision: 2, Authorised, Last updated: 15/12/2020
-
List item
Human medicine European public assessment report (EPAR): Olumiant
baricitinib, Arthritis, Rheumatoid
Date of authorisation: 13/02/2017,, Revision: 8, Authorised, Last updated: 15/12/2020
-
List item
Human medicine European public assessment report (EPAR): Blenrep
belantamab mafodotin, Multiple Myeloma
Date of authorisation: 25/08/2020,, , , Authorised, Last updated: 15/12/2020
-
List item
Human medicine European public assessment report (EPAR): Xeljanz
tofacitinib citrate, Arthritis, Rheumatoid
Date of authorisation: 21/03/2017,
Date of refusal: 25/04/2013,
, , Revision: 15, Authorised, Last updated: 14/12/2020
-
List item
Human medicine European public assessment report (EPAR): Imvanex
modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus, Smallpox Vaccine
Date of authorisation: 31/07/2013,, 
, Revision: 18, Authorised, Last updated: 14/12/2020
-
List item
Human medicine European public assessment report (EPAR): Orkambi
Lumacaftor, ivacaftor, Cystic Fibrosis
Date of authorisation: 18/11/2015,, Revision: 24, Authorised, Last updated: 14/12/2020
-
List item
Human medicine European public assessment report (EPAR): Epclusa
Sofosbuvir, velpatasvir, Hepatitis C, Chronic
Date of authorisation: 06/07/2016,, 
, Revision: 13, Authorised, Last updated: 11/12/2020
-
List item
Human medicine European public assessment report (EPAR): Tysabri
natalizumab, Multiple Sclerosis
Date of authorisation: 27/06/2006,, Revision: 32, Authorised, Last updated: 11/12/2020
-
List item
Human medicine European public assessment report (EPAR): Ibrance
palbociclib, Breast Neoplasms
Date of authorisation: 09/11/2016,, Revision: 11, Authorised, Last updated: 11/12/2020
-
List item
Human medicine European public assessment report (EPAR): Myalepta
Metreleptin, Lipodystrophy, Familial Partial
Date of authorisation: 29/07/2018,, , , Revision: 5, Authorised, Last updated: 10/12/2020
-
List item
Human medicine European public assessment report (EPAR): Kanuma
sebelipase alfa, Lipid Metabolism, Inborn Errors
Date of authorisation: 28/08/2015,, , , Revision: 6, Authorised, Last updated: 10/12/2020
-
List item
Human medicine European public assessment report (EPAR): Kaftrio
ivacaftor, tezacaftor, elexacaftor, Cystic Fibrosis
Date of authorisation: 21/08/2020,, , Revision: 1, Authorised, Last updated: 09/12/2020
-
List item
Human medicine European public assessment report (EPAR): Aybintio
bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms
Date of authorisation: 19/08/2020,, 
, Revision: 1, Authorised, Last updated: 09/12/2020
-
List item
Human medicine European public assessment report (EPAR): Alpivab
Peramivir, Influenza, Human
Date of authorisation: 13/04/2018,, Revision: 2, Withdrawn, Last updated: 09/12/2020
-
List item
Human medicine European public assessment report (EPAR): Zepatier
elbasvir, grazoprevir, Hepatitis C, Chronic
Date of authorisation: 22/07/2016,, Revision: 10, Authorised, Last updated: 08/12/2020
-
List item
Human medicine European public assessment report (EPAR): Neparvis
sacubitril, valsartan, Heart Failure
Date of authorisation: 26/05/2016,, Revision: 10, Authorised, Last updated: 07/12/2020
-
List item
Human medicine European public assessment report (EPAR): Caprelsa
Vandetanib, Thyroid Neoplasms
Date of authorisation: 16/02/2012,, , Revision: 18, Authorised, Last updated: 07/12/2020
-
List item
Human medicine European public assessment report (EPAR): Libtayo
Cemiplimab, Carcinoma, Squamous Cell
Date of authorisation: 28/06/2019,, , Revision: 5, Authorised, Last updated: 07/12/2020
-
List item
Human medicine European public assessment report (EPAR): Onpattro
patisiran sodium, Amyloidosis, Familial
Date of authorisation: 27/08/2018,, , , Revision: 8, Authorised, Last updated: 04/12/2020
-
List item
Human medicine European public assessment report (EPAR): Atriance
nelarabine, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 22/08/2007,, , Revision: 24, Authorised, Last updated: 04/12/2020